Coronary artery disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Participants with acute infection, trauma, burns, surgical history in latest one week; (2) Participants have already received PCI or CABG, or have received other vascular(including: cardio-cerebral vascular and peripheral vascular) interventional treatment; (3) Uncontrolled hypertension (occasional rest blood pressure higher than 160/100mmHg in one week, under drug control), severe ventricular arrhythmia, degree III atrioventricular block; (4) Other heart disease, such as: rheumatic heart disease, pulmonary heart disease, hyperthyroidism heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease, myocarditis, pericarditis; (5) Participants with aortic dissection, aortic aneurysms, pulmonary embolism and severe myocardial bridge; (6) Participants with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure; (7) Participants with liver dysfunction, alanine aminotransferase(ALT)>3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)<30mL/min/1.73m2; (8) Participants with hematopoietic system disease, malignant tumor, autoimmune disorders and infectious disease(tuberculosis, viral hepatitis, syphilis and acquired immune deficiency syndrome); (9) Participants with acute cerebral stroke, severe complications of diabetes(diabetic foot, diabetic ketoacidosis); (10) Participants with organ transplantation; (11) Participants with psychosis or dysgnosia; (12) Pregnant or lactating women; (13) Refusing to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic data;General clinical data;Four Diagnosis of TCM;Coronary angiography; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine examination;Blood biochemical examination;Coagulation index;BNP;Myocardial enzyme;Ultrasonic cardiogram;Electrocardiograph;GRACE risk score; | — |
Countries
China
Contacts
Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences